Form 8-K - Current report:
SEC Accession No. 0001193125-25-007782
Filing Date
2025-01-16
Accepted
2025-01-16 17:11:08
Documents
14
Period of Report
2025-01-10
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d858370d8k.htm   iXBRL 8-K 27803
  Complete submission text file 0001193125-25-007782.txt   184108

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vinc-20250110.xsd EX-101.SCH 2744
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vinc-20250110_def.xml EX-101.DEF 13477
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20250110_lab.xml EX-101.LAB 22414
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20250110_pre.xml EX-101.PRE 14283
16 EXTRACTED XBRL INSTANCE DOCUMENT d858370d8k_htm.xml XML 5349
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 25536354
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)